U.S. markets closed

  • S&P Futures

    4,392.00
    -2.50 (-0.06%)
     

  • Dow Futures

    34,877.00
    -10.00 (-0.03%)
     

  • Nasdaq Futures

    14,847.75
    -1.50 (-0.01%)
     

  • Russell 2000 Futures

    2,153.70
    -1.30 (-0.06%)
     

  • Crude Oil

    64.63
    -0.83 (-1.27%)
     

  • Gold

    1,788.40
    +4.00 (+0.22%)
     

  • Silver

    23.46
    +0.04 (+0.16%)
     

  • EUR/USD

    1.1703
    -0.0018 (-0.15%)
     

  • 10-Yr Bond

    1.2730
    +0.0150 (+1.19%)
     

  • Vix

    21.57
    +3.66 (+20.44%)
     

  • GBP/USD

    1.3745
    -0.0002 (-0.02%)
     

  • USD/JPY

    109.9010
    +0.1410 (+0.13%)
     

  • BTC-USD

    44,884.18
    +210.43 (+0.47%)
     

  • CMC Crypto 200

    1,126.10
    -2.59 (-0.23%)
     

  • FTSE 100

    7,169.32
    -11.79 (-0.16%)
     

  • Nikkei 225

    27,585.91
    0.00 (0.00%)
     

Illumina closes $7.1 billion deal for cancer test maker Grail amid regulatory hurdles

  • Oops!
    Something went wrong.
    Please try again later.
FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego, California
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) -Illumina Inc has completed its $7.1 billion acquisition of cancer detection test maker Grail Inc, it said on Wednesday amid challenges posed by the U.S. Federal Trade Commission and the European Union antitrust regulators.

The life sciences company said there is no legal impediment to the closure in the United States and that the move will ensure the deal does not expire before the regulatory processes conclude.

The U.S. antitrust regulator did not immediately respond to Reuters request for comment.

The cash-and-stock deal was announced in September last year by Illumina to gain access to Grail's flagship Galleri blood test used to diagnose cancers at early stages when the disease is easier to treat.

The deal will face a trial https://bit.ly/3z1pbHV on Aug. 24 at the FTC, which had in March filed a complaint seeking to block the deal, arguing that Illumina is the sole provider of the DNA sequencing that Grail uses and could prevent others from entering the market.

EU antitrust regulators in July opened a full-scale investigation after warning that the deal could curb innovation and competition.

The company said on Wednesday it would hold Grail as a separate company during the European Commission's ongoing regulatory review.

"We will abide by any outcome ultimately reached by the courts," Charles Dadswell, general counsel of Illumina, said.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)

Recommended Stories

  • Top Brazil Aluminum Maker to Expand in Bet on Global Shortfall

    (Bloomberg) -- The aluminum unit of Brazilian conglomerate Votorantim SA is betting on a shortfall of the metal used in everything from beer cans to plane parts.Cia. Brasileira de Aluminio plans to invest 4 billion reais ($748 million) in the next five years as it overhauls and expands operations, Chief Executive Officer Ricardo Carvalho said in an interview. The company that made its Brazilian trading debut in July after a 1.4 billion-real offering also wants to do deals along the value chain.

  • AstraZeneca CEO Soriot tops FTSE 100 pay-out charts in 2020 - report

    Pascal Soriot, the chief executive of COVID-19 vaccine maker AstraZeneca, was Britain's highest paid company boss in 2020, a year when the average FTSE 100 leader saw their pay fall by almost a fifth, a report on Thursday showed. Soriot, whose handling of the pandemic response has drawn criticism despite the company producing its vaccine at cost price, took home 15.45 million pounds ($21.25 million), a report from the High Pay Centre said.

  • Illumina Stock Earns Membership In Elite Club

    Illumina saw its IBD SmartSelect Composite Rating jump to 97 Tuesday, up from 93 the day before. Is Illumina stock on your radar? The new rating shows Illumina stock is outpacing 97% of all stocks when it comes to the most important stock-picking criteria.

  • BlackRock Joins $200 Million in Funding for Startup Breeze Air

    (Bloomberg) -- BlackRock Inc. and Knighthead Capital Management are investing in a $200 million second round of capital to support the expansion of startup low-cost carrier Breeze Airways. The funding also includes additional investments by Peterson Partners Inc. and Sandlot Partners, which helped provide an initial $100 million in capital that backed the May start of flights by the Salt Lake City-based carrier, Breeze Aviation Group Inc. said Wednesday.Breeze, which offers nonstop flights from

  • Cisco Predicts Profit Squeeze on Higher Supply Costs

    (Bloomberg) -- Cisco Systems Inc., the biggest maker of computer networking equipment, gave a lukewarm profit forecast for the fiscal year, saying earnings are being squeezed by the higher costs of parts and supply chain challenges that surfaced during the pandemic.Earnings, excluding some items, will be $3.38 to $3.45 a share in the fiscal year ending next July, the San Jose, California-based company said Wednesday in a statement. Analysts, on average, projected $3.41 a share. Revenue will incr

  • Billionaire George Soros Pulls the Trigger on These 3 Stocks

    Few investors have realized better sustained profits than George Soros. His hedge fund’s annualized returns exceeded 30% for over 30 years, and made him one of the world’s richest men. He gained fame in 1992 when he made a famous bet against the Pound Sterling and generated over $1 billion in profits in just 24 hours. While his political activities have generated controversy and criticism, no one can doubt his financial acumen. He bases that acumen on a simple aphorism: “If investing is entertai

  • US health officials call for booster shots against COVID-19

    U.S. health officials Wednesday announced plans to dispense COVID-19 booster shots to all Americans to shore up their protection amid the surging delta variant and signs that the vaccines' effectiveness is slipping. The plan, as outlined by the chief of the Centers for Disease Control and Prevention and other top health authorities, calls for an extra dose eight months after people get their second shot of the Pfizer or Moderna vaccine. “Our plan is to protect the American people, to stay ahead of this virus,” CDC Director Dr. Rochelle Walensky said as the agency cited a raft of studies suggesting that the vaccines are losing ground while the highly contagious variant spreads.

  • The Ultimate Warren Buffett Stock Is Near Buy Point, But Should You Buy It?

    Berkshire Hathaway is the ultimate Warren Buffett stock. But is it a good buy? Here's what the earnings and chart show for Berkshire stock.

  • COVID-19 symptoms and the Delta variant

    U.S. scientists are investigating whether fully vaccinated people are experiencing different symptoms with the Delta variant than with prior variants.

  • Nvidia earnings top Street view with record data-center, gaming revenue, but supply constraints still a concern

    Nvidia Corp. shares rose in the extended session Wednesday after the chip maker's earnings topped Wall Street estimates and the company addressed how supply constraints in the ongoing global chip shortage were reflected in its outlook.

  • Afghanistan Watchdog Offers Bleak Assessment of US Reconstruction Effort

    A watchdog overseeing the American effort to rebuild Afghanistan offered a tough assessment this week of where things stand in the war-torn country as U.S. troops withdraw. “If the goal was to rebuild and leave behind a country that can sustain itself and pose little threat to U.S. national security interests, the overall picture is bleak,” wrote John Sopko, the Special Inspector General for Afghanistan Reconstruction, in a report titled “What We Need to Learn: Lessons from Twenty Years of Afgha

  • Tesla, Facebook, Twitter, Howmet Aerospace, Snapchat, Pinterest: How Paul Singer's Elliott Management Adjusted Its Portfolio In Q2

    Elliott Investment Management sold Tesla Inc (NASDAQ: TSLA) convertible notes worth $620 million, bought more than $240 million in Twitter Inc (NYSE: TWTR) and exited Facebook Inc (NASDAQ: FB) during the second quarter, regulatory filings revealed on Tuesday. The Trades: The New York-based hedge fund, which manages assets worth $42 billion, also shed its positions in Howmet Aerospace Inc (NYSE: HWM) and Snapchat parent Snap Inc (NYSE: SNAP). Meanwhile, it slightly increased stake in social media

  • Nvidia Q2 revenue jumps 68% on strength of gaming and data center businesses

    Yahoo Finance's Dan Howley breaks down Nvidia's Q2 earnings report.

  • Why Nio Stock Rebounded Today

    Shares of Nio (NYSE: NIO) have been on a steady decline over the past seven trading days. Nio reported its quarterly financial results last week, and some investors weren't adequately impressed. The automaker has also been caught in a net of U.S.-listed Chinese names that have taken hits due to Chinese government regulators who have taken aim at certain technology industries.

  • Afghanistan has 22 tons of gold in a New York vault. The Taliban can’t touch it.

    The Biden administration has frozen the Afghanistan government's holdings in US banks, preventing the Taliban from accessing billions of dollars—including $1.25 in gold bullion in a New York bank vault.

  • 10 Dividend Stocks with Over 20 Years of Dividend Increases

    In this article, we will be taking a look at 10 dividend stocks with over 20 years of dividend increases. To skip our detailed analysis of dividend investing, you can go directly to see the 5 Dividend Stocks with Over 20 Years of Dividend Increases. Typical dividend stocks are known to be some of the most […]

  • Cisco Earnings Matched Expectations. Why the Stock Is Falling.

    Shares of Cisco Systems fell in late trading Wednesday after reporting July quarter results and fiscal year 2022 guidance that largely matched expectations. For the quarter, Cisco (ticker: CSCO) posted revenue of $13.12 billion, up 8% from a year ago and at the high end of the company’s forecast range of 6% to 8% growth. Non-GAAP profit were 84 cents a share, toward the high end of the company’s guidance range of 81 to 85 cents a share.

  • Time to Take Profits in Amazon.com (AMZN)?

    Nelson Capital Management, an investment management firm, published its second-quarter 2021 investor letter – a copy of which can be downloaded here. In the letter, the fund discussed their economic overview, their asset transactions, tax updates, featured equity, and a special topic about the housing bubble. You can view the fund’s top 5 holdings to […]

  • Why Did the Stock Market Just Take a Late-Day Dive?

    The stock market remained relatively flat during much of the day on Wednesday. However, significant movements in long-term Treasury bond yields led some committee members to conclude that market participants don't necessarily believe that price stability is a given.

  • Where Will Palantir Be in 5 Years?

    Palantir (NYSE: PLTR) is a divisive stock. The bulls believe the data mining firm will continue to expand across the government and commercial sectors, while the bears believe it's too dependent on government contracts, its commercial business faces too many competitors, and its stock is too expensive. Palantir's volatility reflects that battle.